CellFE

• 28/09/2023
• Series A
• $22,000,000

CellFE is a cell engineering startup that enables development and manufacturing of the new generation of medicines – cell therapies. CellFE has developed a unique microfluidic platform to solve one of the most pressing issues of therapeutic cell engineering –efficiently delivering gene-editing molecules into cells while preserving cell viability. CellFE’s technology:
• Enables development of previously inaccessible cell therapies by providing means for transporting hard-to-deliver molecules into the cells.
• Accelerates commercialization of existing cell therapies by significantly reducing cost, complexity, and processing time, while improving the efficacy and safety of the cell engineering process.

---

---